NU-9 targets a shared underlying mechanism found in various neurodegenerative diseases. A new study from Northwestern ...

In animal models, NU-9 was found to show promise in treating Alzheimer's by reducing toxic protein buildup and brain ...

While misfolded SOD1 proteins (among others) cause ALS, misfolded amyloid beta oligomers cause Alzheimer's disease. "These ...

ProMIS expects to report six-month interim results from PRECISE-AD in the first half of 2026, with topline results anticipated by the end of 2026. We anticipate the six-month interim analysis will ...

Patients carrying 2 copies of the APOE4 gene (APOE4/4 homozygotes) are more likely to develop AD earlier in life than those without APOE4.

While misfolded SOD1 proteins (among others) cause ALS, misfolded amyloid beta oligomers cause Alzheimer's disease. "These are good proteins gone bad," Klein said. "They are good proteins ...

(NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today ...

A consequence of this is that toxic amyloid-beta oligomers (small clumps of amyloid-beta protein) may “sneak in” to the neurons via this same receptor. Conversely, the SN expresses a selective ...

(NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today ...

A consequence of this is that toxic amyloid-beta oligomers (small clumps of amyloid-beta protein) may "sneak in" to the neurons via this same receptor. Conversely, the SN expresses a selective ...